Publications
111
Citations
1,947
Est. group size
~3
Recurring co-author estimate
Active years
45
Publishing since 1982
Priyanka Mehta's research focuses on acute myeloid leukemia (AML) and related blood cancers, particularly evaluating treatment regimens such as CPX-351, venetoclax combinations, and gemtuzumab ozogamicin through large UK clinical trials (e.g., NCRI AML17, AML18, AML19). This work examines how patient fitness, genetic mutations (like NPM1 and FLT3), and measurable residual disease affect treatment choice and outcomes, especially in older or higher-risk patients. A prospective student would engage with clinical trial data analysis, real-world treatment outcomes research, and consensus-building efforts to improve AML care pathways.
Publication output has grown substantially over the past decade, rising from around 4 papers per year in 2017 to a peak of 17 in 2022-2023, with continued strong activity averaging over 11 papers per year in the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 0980 Benzodiazepine and Z-Drug Use in Adults with Obstructive Sleep Apnea and Cardiometabolic Comorbidities: A Retrospective Cohort Analysis
SLEEP · 2026
- 1252 Struggling for Air? A Cross-Sectional Analysis of Sleep Apnea Guidance on Social Media
SLEEP · 2026
- 1126 Increased Risk of Sleep Disorders Among Individuals with Substance Use Disorders: A Large-Scale EHR-Based Analysis
SLEEP · 2026
- Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Blood · 2026
- CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial
Leukemia & lymphoma/Leukemia and lymphoma · 2026
- A Delphi Consensus on Optimising the Care Pathway for Adult Patients With Acute Myeloid Leukaemia (AML): Strategies to Enhance Transplant Accessibility and Feasibility in the United Kingdom
eJHaem · 2026
- Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood Advances · 2025
- Cervical cancer stage distribution and survival outcomes in Africa: a systematic review and meta-analysis
International Journal of Gynecological Cancer · 2025
- Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Journal of Clinical Oncology · 2025
- CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial
Blood · 2025
- Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel
Frontiers in Oncology · 2025
- FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials
Blood · 2025
- Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis
Blood · 2025
- Real-world analysis of time spent at home for patients with secondary acute myeloid leukemia treated with CPX-351 or venetoclax plus azacitidine in England
Blood · 2025
- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
Journal of Clinical Oncology · 2024
- Blood×24
- British Journal of Haematology×7
- HemaSphere×6
- Blood Advances×4
- Clinical Lymphoma Myeloma & Leukemia×4
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Krzysztof Mrózek
Medicine · The Ohio State University
- Uma Borate
Medicine · The Ohio State University
- Jessica Kohlschmidt
Medicine · The Ohio State University
- Alice S. Mims
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile